The three-way study examined the safety and effectiveness of Novartis' Lucentis and Regeneron/Bayer's Eylea, both licensed to treat diabetic macular oedema (DME) and Roche/Genentech's Avastin ...

ranibizumab (Lucentis) +11]. "In this independent, government-sponsored diabetic macular oedema study, Eylea provided significantly greater efficacy, despite one fewer injection and fewer laser ...

Bayer has overturned a ruling that it brought discredit on the pharma industry. | Bayer has overturned a ruling that it ...

The company announced 27 abstracts at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting ...

It is based on data from the Eylea HD clinical programme, including the Phase III QUASAR study assessing the injection in RVO. The active-controlled Phase III trial is assessing Eylea HD's safety ...

or Eylea 2 mg dosed every four weeks. The study’s primary endpoint was change in best corrected visual acuity (BCVA) at week 36, assessed by Early Treatment Diabetic Retinopathy Study letter score.

a network meta-analysis comparing EYLEA HD and faricimab efficacy and injection frequency, and a modeling study assessing the economic benefits of EYLEA HD versus faricimab over three years.

Eylea, or aflibercept, had global sales of just under $10 billion in 2024, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ...

WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...